Stemline Therapeutics Inc Received its Third Buy in a Row


After Roth Capital and Cowen & Co. gave Stemline Therapeutics Inc (NASDAQ: STML) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ: STML) today and set a price target of $38. The company’s shares closed on Friday at $16.55.

Selvaraju commented:

“Valuation and risks. Our 12-month price target is derived from a discounted cash flow-based asset value of $1.1B for 15% discount rate and 2% terminal growth rate. Probabilities of success ascribed to SL-401 and SL-701 are 90% and 45%, respectively.”

According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 1.0% and a 42.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Currently, the analyst consensus on Stemline Therapeutics Inc is a Strong Buy with an average price target of $34, representing a 105.4% upside. In a report issued on June 12, Roth Capital also initiated coverage with a Buy rating on the stock with a $30 price target.

.

See today’s analyst top recommended stocks >>

Based on Stemline Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $18.42 million. In comparison, last year the company had a GAAP net loss of $14.57 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts